Cantor Fitzgerald Forecasts Cabaletta Bio FY2026 Earnings

Cabaletta Bio, Inc. (NASDAQ:CABA) – Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Cabaletta Bio in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will earn ($0.95) per share for the year. The consensus estimate for Cabaletta Bio’s current full-year earnings is ($2.34) per share.

Several other equities analysts have also weighed in on the company. Wells Fargo & Company cut their price target on Cabaletta Bio from $6.00 to $3.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 1st. UBS Group lowered their target price on Cabaletta Bio from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st. Guggenheim lifted their price target on shares of Cabaletta Bio from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, May 15th. Citigroup cut their target price on Cabaletta Bio from $17.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, May 16th. Finally, Morgan Stanley cut their price objective on Cabaletta Bio from $30.00 to $22.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 1st. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $20.33.

Cabaletta Bio Stock Performance

NASDAQ CABA opened at $1.75 on Wednesday. The stock has a 50-day simple moving average of $1.52 and a two-hundred day simple moving average of $2.03. The firm has a market capitalization of $88.80 million, a P/E ratio of -0.81 and a beta of 2.81. Cabaletta Bio has a fifty-two week low of $0.99 and a fifty-two week high of $13.50.

Cabaletta Bio (NASDAQ:CABA) last announced its earnings results on Wednesday, May 21st. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.04).

Institutional Investors Weigh In On Cabaletta Bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CABA. Miller Financial Services LLC bought a new stake in shares of Cabaletta Bio in the 4th quarter worth about $33,000. Intech Investment Management LLC grew its position in Cabaletta Bio by 42.2% in the 4th quarter. Intech Investment Management LLC now owns 20,203 shares of the company’s stock worth $46,000 after purchasing an additional 5,999 shares during the last quarter. Tudor Investment Corp ET AL bought a new position in shares of Cabaletta Bio in the fourth quarter valued at approximately $47,000. Callan Family Office LLC bought a new position in shares of Cabaletta Bio in the first quarter valued at approximately $58,000. Finally, Comerica Bank boosted its holdings in Cabaletta Bio by 2,292.1% during the first quarter. Comerica Bank now owns 41,599 shares of the company’s stock worth $58,000 after buying an additional 39,860 shares in the last quarter.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.